Navigation Links
12-Month Study Reports Efficacy Rates for AMS' Elevate Apical and Posterior Prolapse Repair System

MINNEAPOLIS, Sept. 21 /PRNewswire/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of a 12-month single-arm, prospective multi-center study of the Elevate® Apical and Posterior Prolapse Repair System.  The pelvic organ prolapse quantification exam (POP-Q), used to quantify, describe, and stage pelvic support, was implemented in the study and concluded efficacy rates of Stage 1 or less to be 89.2% for Apical and 91.7% for Posterior.

The results presented at IUGA/ICS meeting also show that 98.4% of patients treated with the Elevate system would recommend the procedure to a friend.  The study was conducted at sixteen centers in the U.S., Canada, Belgium and UK.

Elevate is a minimally invasive, comprehensive solution to treat apical and posterior defects.  The total transvaginal approach is designed to minimize tissue trauma.  Elevate offers safe, simple and precise apical mesh placement in the sacrospinous ligament through a single vaginal incision.

"Our findings indicate that Elevate offers a prolapse repair technique that is safe with low morbidity and minimal postoperative pain," said Dr. James Lukban, principal investigator of the study.  "Our study concluded that Elevate Apical and Posterior is effective in terms of anatomic correction and improvement in day-to-day symptoms at one year, with ongoing analysis through 24 months."

"Over 34 million women worldwide are affected by vaginal prolapse.  This study provides reliable data that can help patients and their doctors make decisions about treatment options to improve quality of life and restore pelvic anatomy," stated John Nealon, senior vice president and general manager of Women's Health at AMS.

The Elevate Apical and Posterior Prolapse Repair System is part of American Medical Systems' comprehensive portfolio of products designed to treat female incontinence and pelvic floor conditions.  For more information about AMS' complete line of female pelvic health solutions, visit

About American Medical Systems:

American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to cure stress incontinence, erectile dysfunction, benign prostatic  hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women.  These disorders can significantly diminish one's quality of life and profoundly affect social relationships.  In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives.  American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies.  The Company's products were used to treat more than 335,000 patients in 2009.

More information about the Company and its products can be found at its website and in the Company's Annual Report on Form 10-K for 2009 and its other SEC filings.

SOURCE American Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
2. 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
3. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
4. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
5. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
6. Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
7. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
8. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
9. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):